Cover Image

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib

Abstract Futibatinib is a covalently binding FGFR1-4 inhibitor that received US Food and Drug Administration approval for the treatment of patients with previously treated, advanced intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements. This phase I trial evaluated the pharmaco...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ling Gao (Author), Ikuo Yamamiya (Author), Mark Pinti (Author), Juan Carlos Rondon (Author), Thomas Marbury (Author), Gareth Tomlinson (Author), Lukas Makris (Author), Nanae Hangai (Author), Volker Wacheck (Author)
Format:	Book
Published:	Wiley, 2023-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A phase I drug-drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
by: Amanda Long, et al.
Published: (2024)

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
by: Smith WB, et al.
Published: (2012)

Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment
by: Mirjam Kuipers, et al.
Published: (2006)

Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
by: Wei Yin, et al.
Published: (2024)

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
by: Cheng Y, et al.
Published: (2023)

Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
by: Masaya Tachibana, et al.
Published: (2023)

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
by: Marbury T, et al.
Published: (2017)

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
by: Kim S, et al.
Published: (2014)

Pharmacokinetic profile of defibrotide in patients with renal impairment
by: Tocchetti P, et al.
Published: (2016)

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study
by: Andrew D. Hershey, et al.
Published: (2024)

Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open‐label randomized cross‐over study in healthy subjects
by: Alison Luckey, et al.
Published: (2023)

Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
by: Wang X, et al.
Published: (2020)

Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects
by: Liu J, et al.
Published: (2023)

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
by: Nicolino Ruperto, et al.
Published: (2017)

Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
by: Rajinder Bhardwaj, et al.
Published: (2024)

Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets
by: Feng Z, et al.
Published: (2022)

Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study
by: Thierry Passeron, et al.
Published: (2024)

Open-label phase I clinical trial of Ad5-EBOV in Africans in China
by: Lihua Wu, et al.
Published: (2017)

An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
by: Astrid De Meulenaere, et al.
Published: (2021)

Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects
by: He X, et al.
Published: (2024)

Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial
by: Ni Y, et al.
Published: (2024)

Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study
by: Yanli Wang, et al.
Published: (2023)

Pharmacokinetic Interactions Between Bazedoxifene and Cholecalciferol: An Open-Label, Randomized, Crossover Study in Healthy Male Volunteers
by: Lee MH, et al.
Published: (2023)

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
by: Hitoshi Tajiri, et al.
Published: (2019)

Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
by: Manu Chaudhary, et al.
Published: (2018)

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
by: van Rossem K, et al.
Published: (2013)

Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials
by: Abhijeet Jakate, et al.
Published: (2021)

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
by: Taro Kishi, et al.
Published: (2019)

Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers
by: Huang J, et al.
Published: (2018)

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies
by: Cuiping Chen, et al.
Published: (2021)

Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
by: John M. Slopis, et al.
Published: (2018)

Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Patients Undergoing Procedure-Type Sedation
by: Edmund H. Jooste, et al.
Published: (2017)

Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers
by: Kim H, et al.
Published: (2018)

Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers
by: Kim YH, et al.
Published: (2015)

An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch
by: Zhang C, et al.
Published: (2017)

Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
by: Li G, et al.
Published: (2018)

Atomoxetine Open-Label Trial in ADHD
by: J Gordon Millichap
Published: (2002)

Efficacy and safety of Cineole (Soledum®) in the treatment of patients with acute bronchitis: results of an open-label randomized clinical phase III study
by: Peter Kardos, et al.
Published: (2021)

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults
by: Erin M. Paradis, et al.
Published: (2021)

Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study
by: Ileana Gutiérrez-Farfán, et al.
Published: (2021)